Clinical Trial


Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia


Brief description

The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.

Keywords

  •   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

Sponsored By

AstraZeneca

Unique Study ID

NCT02104817

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Sanofi
B15 2GW, Birmingham, United Kingdom
Distance from Current Trial is 0 miles

Jereme D Wilroy, PhD

University of Alabama at Birmingham
35209, Birmingham, Alabama, United States
Distance from Current Trial is 0 miles

Ansar Mahmood

University of Aberdeen
B15 2TH, Birmingham, United Kingdom
Distance from Current Trial is 0 miles
View All